D. Barnd

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

V. Engelhard, C. Slingluff, W. Grosh, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

R. Bast, J. Taylor‐Papadimitriou, K. Jerome, 1991, Cancer research.

Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1.

J. Berzofsky, R. Houghten, D. Barnd, 1992, Journal of immunology.

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

V. Engelhard, W. Grosh, G. Petroni, 2001, International journal of cancer.

Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells1

R. Bast, J. Taylor‐Papadimitriou, K. Jerome, 2006 .

Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells 1

R. Bast, J. Taylor‐Papadimitriou, K. Jerome, 2006 .

Human tumor-specific cytotoxic T cell lines generated from tumor-draining lymph node infiltrate.

R. Metzgar, D. Barnd, O. Finn, 1988, Transplantation proceedings.

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

M. Lan, R. Metzgar, D. Barnd, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Assessment of the Toxicities of Systemic Low-Dose Interleukin-2 Administered in Conjunction with a Melanoma Peptide Vaccine

E. Bissonette, C. Slingluff, W. Grosh, 2004, Journal of immunotherapy.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

E. Bissonette, C. Slingluff, W. Grosh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope.

J. Berzofsky, R. Houghten, M. Clerici, 1991, The Journal of infectious diseases.